Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 1/20 | 0.50 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.50 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.50 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.50 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.49 |
| ▸ | MMP13 | P45452 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 3/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1249505 | 1.00 | EED (0.50) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL1249862 | 0.87 | USP30 (0.48) | GPR119USP30 | |
| SCHEMBL1249860 | 0.87 | USP30 (0.48) | GPR119USP30 | |
| SCHEMBL1249864 | 0.87 | USP30 (0.48) | GPR119USP30 | |
| SCHEMBL13044647 | 0.84 | GPR119 (0.46) | GPR119MMP13KDM4EPKMMMP1 | |
| SCHEMBL31602756 | 0.83 | GPR119 (0.56) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL19297084 | 0.83 | GPR119 (0.49) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL3786536 | 0.81 | EED (0.50) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL3852714 | 0.81 | EED (0.50) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL19617395 | 0.81 | GPR119 (0.49) | EEDRBBP4SUZ12EZH2AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2283000-B1 | 3- OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2015-09-23 | — | — | EP | disclosed |
| US-8546576-B2 | 3 or 4-substituted piperidine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-10-01 | — | — | US | disclosed |
| US-8513285-B2 | 3 or 4-substituted piperidine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-08-20 | — | — | US | disclosed |
| US-20120122927-A1 | 3 OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS | LEE KI-HO (KR) | 2012-05-17 | — | — | US | disclosed |
| EP-2283000-A2 | 3- OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS | SK Holdings Co., Ltd. (KR) | 2011-02-16 | — | — | EP | disclosed |
| US-20090306140-A1 | 3 or 4-Substituted Piperidine Compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-12-10 | — | — | US | disclosed |
| WO-2009148291-A2 | 3- OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS | SK HOLDINGS CO., LTD. (KR) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122927-A1 | 3 OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS | OPRD1, OPRK1, OPRM1 | EED 803/4885RBBP4 767/4885SUZ12 2684/4885 |
| US-20090306140-A1 | 3 or 4-Substituted Piperidine Compounds | OPRD1, OPRK1, OPRM1 | EED 879/4885RBBP4 805/4885SUZ12 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.